Longevity Weekly Podcast

This week's pattern is unmistakable: the institutions that treat aging as a design challenge, not a demographic crisis, are pulling ahead. Nobel laureate Daron Acemoglu argues that faster-aging nations invested more in automation, turning a supposed liability into a competitive advantage. 

Stanford researchers have built a machine-learning tool that reads resting-state brain scans and sorts cognitively healthy seniors into “SuperAger-like” and “Alzheimer-like” subgroups, years before any memory test detects a difference. And some important news...

This week's longevity landscape reveals a striking convergence: governments, institutions, and researchers are moving from studying the aging challenge to building the infrastructure for longer, more productive lives. The 2026 Global Pension Index exposes a sustainability gap even among top-ranked retirement systems, while China embeds the silver economy directly into its national five-year plan.

This week, the longevity field crossed a threshold from ambition to infrastructure, with institutions across science, finance, and policy all moving to build systems worthy of 100-year lives. 

This week marks a shift from diagnosing the longevity challenge to building the institutions that might actually solve it, and the distance between ambition and execution has never been clearer.

Something shifted this week in how institutions treat aging. At Harvard, five of the world's largest pharmaceutical companies discussed targeting aging itself, not just its diseases. 

This week, the world’s most powerful institutions stopped treating Longevity as a future problem.

The world has crossed a demographic threshold it will never cross back. For the first time in history, people over 65 outnumber children under five globally, and the pace is accelerating:

The brain does not age in a straight line. It undergoes a dramatic transformation between 50 and 75. 

What actually slows biological aging? A landmark Yale study just analyzed 51 clinical trials to find out—and supplements didn't make the cut.